MetaCap

Equillium (EQ) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Equillium (EQ) has outperformed Upstream Bio (UPB) over the past year, gaining 10.4% versus a loss of 93.8%. Equillium is the larger company by market cap ($87.3 million vs $87.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EQ+10.42%UPB-93.78%
+250%+70%-110%
Nov 21, 20251 yearNov 20, 2026
EQ+15.22%UPB-92.77%
+248%+69%-109%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EQ versus UPB key metrics
MetricEQUPB
Share price$1.06$1.59
Market cap$87.26M$87.15M
1-day change-5.36%-20.50%
YTD return-31.61%-94.14%
1-year return+10.42%-93.78%
5-year return-80.41%—
EPS (TTM)$-0.12$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)$-22.40M$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$3.54$33.68
52-week low$0.81$1.56
Distance from 52-week high-70.06%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+707.55%+1245.91%
Average volume544.39K1.01M
Shares outstanding82.32M54.81M
Employees1475
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EQ has outperformed UPB by 104.2 percentage points over the past year.

About Equillium

EQ stock →

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

EQ vs UPB FAQ

Which is bigger, Equillium or Upstream Bio?

Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $87.15M for Upstream Bio (UPB).

Which stock has performed better over the past year, EQ or UPB?

EQ returned +10.42% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are Equillium and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons